Brokerages predict that OptiNose Inc (NASDAQ:OPTN) will report $7.74 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for OptiNose’s earnings, with estimates ranging from $6.70 million to $8.77 million. OptiNose posted sales of $1.27 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 509.4%. The business is expected to announce its next earnings results on Tuesday, August 13th.

On average, analysts expect that OptiNose will report full year sales of $34.46 million for the current year, with estimates ranging from $31.20 million to $37.73 million. For the next fiscal year, analysts anticipate that the business will report sales of $83.12 million, with estimates ranging from $75.90 million to $90.35 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow OptiNose.

OptiNose (NASDAQ:OPTN) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.01. OptiNose had a negative return on equity of 81.04% and a negative net margin of 983.22%. The business had revenue of $4.48 million during the quarter, compared to analysts’ expectations of $4.35 million.

Several research firms have weighed in on OPTN. Zacks Investment Research cut OptiNose from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 price objective on shares of OptiNose in a report on Thursday, May 9th. Piper Jaffray Companies set a $29.00 price objective on OptiNose and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Finally, Royal Bank of Canada dropped their price objective on OptiNose to $25.00 and set an “outperform” rating for the company in a report on Thursday, March 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $27.80.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP bought a new position in shares of OptiNose in the 4th quarter worth approximately $493,000. Two Sigma Advisers LP bought a new position in shares of OptiNose in the 4th quarter worth approximately $135,000. Broadfin Capital LLC bought a new position in shares of OptiNose in the 4th quarter worth approximately $4,406,000. American Century Companies Inc. raised its position in shares of OptiNose by 19.1% in the 4th quarter. American Century Companies Inc. now owns 242,616 shares of the company’s stock worth $1,504,000 after acquiring an additional 38,842 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of OptiNose by 39.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,874,231 shares of the company’s stock worth $23,297,000 after acquiring an additional 526,501 shares in the last quarter. Institutional investors and hedge funds own 63.68% of the company’s stock.

NASDAQ OPTN traded down $0.06 on Friday, hitting $6.90. The company’s stock had a trading volume of 150,961 shares, compared to its average volume of 202,788. OptiNose has a 52-week low of $5.66 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.74 and a current ratio of 6.95. The stock has a market cap of $287.20 million, a P/E ratio of -2.57 and a beta of 1.09.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Further Reading: What is the Consumer Price Index (CPI)?

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.